From PvP Biologics Raises $35M in a Lab-to-Pharma Deal with Takeda:

KumaMax Enzyme (Image by Vikram Mulligan:Univ. Wash., used with permission)

KumaMax Enzyme (Image by Vikram Mulligan:Univ. Wash., used with permission)—

Computer-generated image of KumaMax Enzyme (Image by Vikram Mulligan:Univ. Wash., used with permission)

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
What to Include in Your Life Sciences Company Fundraising Pitch Deck
What the most successful life sciences fundraising pitch decks all have in common
Brex

Sponsored · Whitepaper
Decentralized Clinical Trials: The Call for a New Paradigm
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences

From Our Editors · Special Report
Biopharma and Tech Innovators Summer 2020
The cutting-edge companies behind the innovations disrupting biopharma and revolutionizing the healthcare landscape

Xconomy on Demand

We offer a number of ways to subscribe for free!